PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Cash & equivalents declining -9.79% while Biotechnology shows -1.06% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -1.64%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
Current assets growth ≥ 1.5x the Biotechnology median of -1.57%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-10.21%
PP&E growth ≥ 1.5x the Biotechnology median of -0.46%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
≥ 1.5x the Biotechnology median of -0.73%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
3.20%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-75.32%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Below half Biotechnology median of 4.78%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Below half Biotechnology median of 0.86%. Joel Greenblatt sees a much lower liability expansion vs. peers.
7.69%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2.53%
Below half Biotechnology median of -5.19%. Jim Chanos suspects poor profitability or large dividend drains.
-4.62%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
≥ 1.5x Biotechnology median of -1.96%. Joel Greenblatt sees stronger equity growth vs. peers.
-9.71%
≥ 1.5x Biotechnology median of -0.95%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
9.58%
Above 1.5x Biotechnology median 2.70%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.